Content overview: “Caribou Biosciences Shuts Down: CRISPR Pioneer Jennifer Doudna’s Biotech Fails to Fund Lym”. Caribou Biosciences, the gene-editing biotech co-founded by Nobel laureate Jennifer Doudna, is shutting down after failing to secure funding for a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma. The company, which was based in Berkeley, California, announced the decision as a result of an inability to raise the necessary capital, underscoring the financial hurdles facing cell therapy developers. Caribou had been working on an allogeneic, or donor-derived, CAR-T treatment, which could offer advantages over personalized autologous therapies, but the cost and complexity of late-stage trials proved insurmountable.
The shutdown marks a significant setback for the field of CRISPR-based cell therapies and highlights the broader challenges of bringing next-generation cancer treatments to market. As the biotech sector faces a tightening funding environment, Caribou’s closure may signal more consolidation and failures among early-stage companies. The full version stays on the original page, which this listing opens directly.